

BESTMED MEDICINE FORMULARY FOR NON-CDL (CHRONIC DISEASE LIST) CONDITIONS

- Benefits are subject to the following:
 - ✓ Pre-authorisation
 - ✓ Bestmed guidelines
 - ✓ Bestmed protocols
 - ✓ MediKredit Reference Price (MMAP)
This is a reference pricing model applicable to all medicines with generic equivalents or biosimilars. MMAP sets the maximum reimbursable price for a list of generically similar or biosimilar products with a cost lower than that of the original medicine. This means that if you opt to use a medicine that is more expensive than the MMAP, you will have to pay the difference between the price of the chosen medicine and that of MMAP.
- This formulary is effective from 1 January 2026.
- This formulary is subject to change without notice.

NEUROPATHY

ACTIVE INGREDIENT	Pace2 Pace3 Pace4
<u>A</u>	
AMITRIPTYLINE 10MG	YES
AMITRIPTYLINE 25MG	YES
<u>C</u>	
CARBAMAZEPINE 200MG	YES
CARBAMAZEPINE CR 200MG	YES
CARBAMAZEPINE CR 400MG	YES
CARBAMAZEPINE 100MG/5ML SUSPENSION	YES
<u>G</u>	
GABAPENTIN 100MG	YES
GABAPENTIN 300MG	YES
GABAPENTIN 400MG	YES
<u>P</u>	
PHENYTOIN 100MG	YES
PHENYTOIN 125MG/5ML SUSPENSION	YES